Efficacy of a novel class of RNA interference therapeutic agents

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Hamasaki, Tomohiro ^a   Suzuki, Hiroshi ^a   Shirohzu, Hisao ^a   Matsumoto, Takahiro ^a,b   D'Alessandro Gabazza, Corina N ^b   Gil Bernabe, Paloma ^b   Boveda Ruiz, Daniel ^b   Naito, Masahiro ^b   Kobayashi, Tetsu ^b   Toda, Masaaki ^b   Mizutani, Takayuki ^a,d   Taguchi, Osamu ^b   Morser, John ^f   Eguchi, Yutaka ^e   Kuroda, Masahiko ^d   Ochiya, Takahiro ^c   Hayashi, Hirotake ^a   Gabazza, Esteban C ^a,b   Ohgi, Tadaaki ^a  

^a BONAC Corporation   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NKRNA; PNKRNA; RNA; SHORT HAIRPIN RNA; SINGLE STRANDED RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLLAGEN DEPOSITION; COLLAGEN METABOLISM; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; EMBRYO; FEMALE; GENE REPRESSION; GENE TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROSIS; MALE; MOUSE; NONHUMAN; OLIGOMERIZATION; PROTEIN SYNTHESIS INHIBITION; RNA DEGRADATION; RNA INTERFERENCE; RNA STABILITY; RNA STRUCTURE; RNA SYNTHESIS;

ACUTE LUNG INJURY; ANIMALS; BASE SEQUENCE; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; MICE; PULMONARY FIBROSIS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84865061173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042655     Document Type: Article

References (25)

1. Sledz CA, Williams BR, (2005) RNA interference in biology and disease. Blood 106: 787-794.
2. Kim DH, Rossi JJ, (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173-184.
3. Bumcrot D, Manoharan M, Koteliansky V, Sah DW, (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719.
4. Kedmi R, Peer D, (2009) RNAi nanoparticles in the service of personalized medicine. Nanomedicine (Lond) 4: 853-855.
5. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK, RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11: 59-67.
6. de Fougerolles AR, (2008) Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 19: 125-132.
7. Chernolovskaya EL, Zenkova MA, Chemical modification of siRNA. Curr Opin Mol Ther 12: 158-167.
8. Lares MR, Rossi JJ, Ouellet DL, RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28: 570-579.
9. Schlee M, Hornung V, Hartmann G, (2006) siRNA and isRNA: two edges of one sword. Mol Ther 14: 463-470.
10. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, et al. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462.
11. Reynolds A, Anderson EM, Vermeulen A, Fedorov Y, Robinson K, et al. (2006) Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 12: 988-993.
12. Watts JK, Corey DR, Silencing disease genes in the laboratory and the clinic. J Pathol 226: 365-379.
13. Wilson MS, Wynn TA, (2009) Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2: 103-121.
14. Wynn TA, (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210.
15. Matthay MA, Zemans RL, The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol 6: 147-163.
16. Abe H, Abe N, Uda M, Tsuneda S, Ito Y, (2009) Synthetic nanocircular RNA for controlling of gene expression. Nucleic Acids Symp Ser (Oxf) pp. 65-66.
17. Abe N, Abe H, Ito Y, (2007) Dumbbell-shaped nanocircular RNAs for RNA interference. J Am Chem Soc 129: 15108-15109.
18. Bartram U, Speer CP, (2004) The role of transforming growth factor beta in lung development and disease. Chest 125: 754-765.
19. Lu Q, Harrington EO, Jackson H, Morin N, Shannon C, et al. (2006) Transforming growth factor-beta1-induced endothelial barrier dysfunction involves Smad2-dependent p38 activation and subsequent RhoA activation. J Appl Physiol 101: 375-384.
20. Madtes DK, Rubenfeld G, Klima LD, Milberg JA, Steinberg KP, et al. (1998) Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 158: 424-430.
21. Pittet JF, Griffiths MJ, Geiser T, Kaminski N, Dalton SL, et al. (2001) TGF-beta is a critical mediator of acute lung injury. J Clin Invest 107: 1537-1544.
22. Willis BC, Kim KJ, Li X, Liebler J, Crandall ED, et al. (2003) Modulation of ion conductance and active transport by TGF-beta 1 in alveolar epithelial cell monolayers. Am J Physiol Lung Cell Mol Physiol 285: L1192-1200.
23. D'Alessandro-Gabazza CN, Kobayashi T, Boveda D, Takagi T, Toda M, et al. (2012) Development and preclinical efficacy of novel transforming growth factor-beta1 siRNAs for pulmonary fibrosis. Am J Respir Cell Mol Biol 46: 397-406.
24. Takagi T, Taguchi O, Aoki S, Toda M, Yamaguchi A, et al. (2009) Direct effects of protein S in ameliorating acute lung injury. J Thromb Haemost 7: 2053-2063.
25. Ashcroft T, Simpson JM, Timbrell V, (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41: 467-470.